97200 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells Carcino-embryonic Antigens
TUMOR-TARGETED SPLIT IL2 RECEPTOR AGONISTS
#2BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#3BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#4BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD3
#5COMBINATION THERAPY WITH FAP-TARGETED LYMPHOTOXIN BETA RECEPTOR AGONISTS
#6COMPOSITIONS TARGETING ENDOTHELIAL CELLS AND USES THEREOF
#7METHODS FOR ABLATING MYELOID DERIVED SUPPRESSOR CELLS USING NEO-201 ANTIBODY
#8ANTIBODIES BINDING TO CEACAM5
#9STABILIZED IMMUNOGLOBULIN DOMAINS
#10TREATMENT METHOD
#11ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF
#12ANTIBODIES SPECIFICALLY BINDING TO CEACAM5
#13ANTIBODIES FOR CHELATED RADIONUCLIDES
#14MODIFIED IMMUNE CELLS
#15DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY
#16DEGRADATION OF EGFR USING A BISPECIFIC BINDING AGENT
#17MULTI-SPECIFIC ANTIBODIES IN USES THEREOF IN AVIDITY RECEPTOR CROSSLINKING AND IMMUNE MODULATION
#18Safety Kill Switches for Engineered Cells Carrying Synthetic Chromosomes
#19ANTI-CD28 ANTIBODIES
#20ANTI-CEACAM5 ANTIBODIES AND USES THEREOF
#21COMBINATION THERAPY WITH TARGETED 4-1BB (CD137) AGONISTS
#22ANTIBODY-DRUG CONJUGATES AND USES THEREOF
#23DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY
#24Monoclonal Antibodies Against Carcinoembryonic Antigens, and Their Uses
#25ANTIBODY AGAINST CEACAM5 AND CEACAM6, AND USE THEREOF
#26COMBINATION THERAPY OF BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47 AND BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD3
#27CEACAM5-DEPENDENT 4-1BB-AGONISTIC BISPECIFIC ANTIBODIES
#28ANTI-CEACAM5 ANTIBODIES AND CONJUGATES AND USES THEREOF
#29METHODS AND TOOLS FOR CONJUGATION TO ANTIBODIES
#30COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-LAG-3 ANTIBODY, A PD-1 PATHWAY INHIBITOR, AND AN IMMUNOTHERAPEUTIC AGENT
#31SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
#32CAR T-CELL THERAPY DIRECTED TO LHR FOR THE TREATMENT OF SOLID TUMORS
#33ANTIBODY-CONJUGATED 8-SULFONYL-BENZAZEPINE COMPOUNDS AND THEIR USES
#34ANTI-CEACAM5 ANTIBODIES AND CONJUGATES AND USES THEREOF
#35Anti-CEA Antibody Drug Conjugates and Methods of Use
#36ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER
#37ANTIBODY-CONJUGATES FOR TARGETING OF TUMOURS EXPRESSING CARCINOEMBYRONIC ANTIGEN
#38COMBINATION THERAPY WITH A CEA X CD28 BISPECIFIC ANTIBODY AND BLOCKING ANTI-PD-1 ANTIBODIES FOR ENHANCED IN VIVO ANTI-TUMOR ACTIVITY
#39BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#40CEA ASSAY FOR PATIENT SELECTION IN CANCER THERAPY
#41PHARMACEUTICAL COMPOSITION CONTAINING TAGGED SITE-ANTIHUMAN ANTIBODY FAB FRAGMENT COMPLEX
#42NATURAL KILLER CELL-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF
#43BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#44MULTISPECIFIC ANTIBODIES AND USES THEREOF
#45CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF
#46ANTIBODY MASKS AND USES THEREOF
#47MULTISPECIFIC ANTIBODIES AND USES THEREOF
#48MULTISPECIFIC ANTIBODIES AND USES THEREOF
#49DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY
#50Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#51METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES
#52FUSION PROTEINS AND USES THEREOF
#53SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
#54FUSION PROTEIN TARGETING BOTH CD3 AND CD137, PREPARATION METHOD THEREFOR AND USE THEREOF
#55Antibody-drug conjugates and uses thereof
#56Fusion Proteins for Dephosphorylating Proteins that Regulate T Cell Activation through the TCR Signaling Pathway
#57BISPECIFIC ANTIBODY AND USE THEREOF
#58HYBRID RECEPTORS WITH MULTIPLE TRANSCRIPTIONAL REGULATORS
#59CEACAM5-dependent 4-1BB-agonistic bispecific antibodies
#60ANTIBODY-UREASE CONJUGATES FOR THERAPEUTIC PURPOSES
#61ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF
#62CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF
#63MUTATED FERRITIN PROTEIN
#64BI-SPECIFIC ANTIBODIES FOR USE IN PRODUCING ARMED IMMUNE CELLS
#65ANTI-CEA ANTIBODIES AND METHODS OF USE
#66ANTI-CEA AND ANTI-CD137 MULTISPECIFIC ANTIBODIES AND METHODS OF USE
#67SYNTHETIC INTERMEMBRANE PROTEOLYSIS RECEPTORS FOR CUSTOM ANTIGEN-INDUCED TRANSCRIPTIONAL REGULATION
#68THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132)
#69Single chain binding molecules comprising N-terminal ABP
#70MOLECULES THAT BIND TO CD66e POLYPEPTIDES
#71COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS
#72NATURAL KILLER CELL ANTIBODIES WITH INCREASED ADCC ACTIVITY
#73DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY
#74DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY
#75PROTEINS BINDING NKG2D, CD16, AND CEACAM5
#76BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47
#77ASSESSMENT OF CEACAM1 EXPRESSION ON TUMOR INFILTRATING LYMPHOCYTES
#78COMBINATION THERAPY OF PD-1-TARGETED IL-2 VARIANT IMMUNOCONJUGATES AND FAP/4-1BB BINDING MOLECULES
#79BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47
#80PREVENTION AND TREATMENT OF STEROID-RESISTANT OR GUT GRAFT-VERSUS-HOST DISEASE (GVHD)
#81SPLIT ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS
#82CONJUGATE OR FUSION PROTEIN FOR CANCER THERAPY
#83PEPTIDE COMPOSITIONS AND METHODS FOR ANTI-CD3 BINDING DOMAINS
#84ANTI-CEACAM5 ANTIBODIES AND CONJUGATES AND USES THEREOF
#85ADOPTIVE CELL THERAPY FOR TREATMENT OF CANCER ASSOCIATED WITH LOSS OF HETEROZYGOSITY
#86Bispecific antibody binding BCMA and CD3
#87TUMOR-TARGETED AGONISTIC CD28 ANTIGEN BINDING MOLECULES
#88COMBINATION TREATMENT
#89Antigen binding receptors specific for mutated Fc domains
#90TREATMENT METHOD
#91ANTI-CEA ANTIBODIES
#92COMBINATION THERAPY WITH TARGETED 4-1BB (CD137) AGONISTS
#93BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#94A NOVEL ANTIBODY BINDING SPECIFICALLY TO HUMAN CEACAM1/3/5 AND USE THEREOF
#95NIR-conjugated tumor-specific antibodies and uses thereof
#96RECEPTORS PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY
#97CHIMERIC ANTIGEN RECEPTOR FOR TREATMENT OF CANCER
#98RECOMBINANT POLYPEPTIDES FOR PROGRAMMING EXTRACELLULAR VESICLES
#99Antibodies against carcinoembryonic antigens
#100CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING CEA AND ANTI-CEA-IL2 IMMUNOCYTOKINES FOR CANCER THERAPY
#101BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD3
#102MINIATURE GUIDANCE AND NAVIGATION CONTROL (miniGNC) ANTIBODY-LIKE PROTEINS AND METHODS OF MAKING AND USING THEREOF
#103COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-LAG-3 ANTIBODY, A PD-1 PATHWAY INHIBITOR, AND AN IMMUNOTHERAPEUTIC AGENT
#104ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES AND FOLFIRI
#105BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#106MESENCHYMAL STEM CELLS TO ENHANCE ANTI-TUMOR ACTIVITY OF IMMUNOTHERAPY
#107RECEPTORS PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY
#108ANTI-CEA ANTIBODY-EXATECAN ANALOG CONJUGATE AND PHARMACEUTICAL USE THEREOF
#109TREATMENT METHOD
#110ANTI-CEA ANTIBODY AND APPLICATION THEREOF
#111Receptors providing targeted costimulation for adoptive cell therapy
#112CELL-TARGETING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES
#113ANTIBODIES FOR CHELATED RADIONUCLIDES
#114BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3
#115Splicing modulator antibody-drug conjugates and methods of use
#116ANTI-CD40 BINDING MOLECULES AND BI-SPECIFIC ANTIBODIES COMPRISING SUCH
#117FUSED PROTEIN OF AN ANTIBODY WHICH RECOGNIZES CANCER-CELLS AND A STREPTAVIDIN MUTANT
#118ANTI-CEACAM5 ANTIBODIES AND USES THEREOF
#119SINGLE CHAIN FUSIONCONSTRUCTS COMPRISING MULTIMERIC ANTIBODY FRAGMENTS FUSED TO COLLAGEN TRIMERIZATION DOMAINS
#120DUAL BISPECIFIC ANTIBODY COMPOUNDS AND USES THEREOF
#121FUSION OF AN ANTIBODY BINDING CEA AND 4-1BBL
#122ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS
#123Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof
#124ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER
#125ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER
#126NOVEL IMMUNOCONJUGATES
#127Anti-CEACAM5 monoclonal antibody and preparation method thereof and use thereof
#128BISPECIFIC NANOBODIES
#129ANTI-CEACAM5 MONOCLONAL ANTIBODY, PREPARATION METHOD THEREOF AND USE THEREOF
#130Bispecific antibodies against CEACAM5 and CD47
#131ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF
#132CHIMERIC ACTIVATORS: QUANTITATIVELY DESIGNED PROTEIN THERAPEUTICS AND USES THEREOF
#133RECEPTORS PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY
#134METHODS AND COMPOSITIONS TO IMPROVE THE SAFETY AND EFFICACY OF CELLULAR THERAPIES
#135CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE
#136MODIFIED FC FRAGMENT, ANTIBODY COMPRISING SAME, AND APPLICATION THEREOF
#137NOVEL ICOS ANTIBODIES AND TUMOR-TARGETED ANTIGEN BINDING MOLECULES COMPRISING THEM
#138CONJUGATE COMPRISING LIGAND AND CEACAM5 ANTIBODY FAB FRAGMENT
#139NOVEL POLYPEPTIDES
#140BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#141SINGLE-DOMAIN ANTIBODY-CYTOSINE DEAMINASE FUSION PROTEINS
#142ANTIBODY-DRUG CONJUGATES AND USES THEREOF
#143TREATMENT METHOD
#144ANTI-CEA ANTIBODIES
#145CHIMERIC ANTIGEN RECEPTOR AND ITS USE
#146CEACAM1 MEDIATED PROTECTIVE IMMUNITY
#147CEACAM1 BASED CANCER THERAPY AND DIAGNOSIS
#148CAR T-CELL THERAPY DIRECTED TO LHR FOR THE TREATMENT OF SOLID TUMORS
#149T CELL RECRUITING POLYPEPTIDES BASED ON TCR ALPHA/BETA REACTIVITY
#150THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132)
#151HOMODIMERIC BISPECIFIC ANTIBODY, PREPARATION METHOD THEREFOR AND USE THEREOF
#152Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
#153COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-LAG-3 ANTIBODY, A PD-1 PATHWAY INHIBITOR, AND AN IMMUNOTHERAPEUTIC AGENT
#154Granulysin, method of obtaining same, and uses
#155Compositions and methods of treating cancer with chimeric antigen receptors
#156Splicing modulator antibody-drug conjugates and methods of use
#157CAR-T LYMPHOCYTES ENGINEERED TO HOME TO LYMPH NODE B CELL ZONE, SKIN, OR GASTROINTESTINAL TRACT
#158NOVEL BISPECIFIC AGONISTIC 4-1BB ANTIGEN BINDING MOLECULES
#159BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#160BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#161TREATMENT METHOD
#162TRIMERIC POLYPEPTIDE COMPLEXES AND USES THEREOF
#163BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47
#164Interleukin-2 and use thereof
#165TARGETING MOIETY-DECORATED ONCOLYTIC VIRUSES
#166Antigen-specific T cells and uses thereof
#167CELL-TARGETING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES
#168BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#169Splicing modulator antibody-drug conjugates and methods of use
#170Anti-CEACAM antibodies and uses thereof
#171Combination therapy with targeted 4-1BB (CD137) agonists
#172Modified cell with enhanced functionality and cellular therapy thereof
#173Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)
#174BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#175Antibody-drug conjugates and uses thereof
#176Stabilized immunoglobulin domains
#177DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY
#178COMPOSITIONS AND METHODS FOR COMBINATION CANCER VACCINE AND IMMUNOLOGIC ADJUVANT THERAPY
#179Chimeric antigen receptor with cytokine receptor activating or blocking domain
#180BISPECIFIC ANTIBODY WITH PROLONGED HALF-LIFE AND ENHANCED ANTI-TUMOR EFFECT
#181C-TERMINALLY FUSED TNF FAMILY LIGAND TRIMER-CONTAINING ANTIGEN BINDING MOLECULES
#182Combination therapy with targeted OX40 agonists
#183BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#184METHODS OF TREATING CEA-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-CEA/ANTI-CD3 BISPECIFIC ANTIBODIES
#185GERIATRIC CAR-T CELLS AND USES THEREOF
#186NIR-CONJUGATED TUMOR-SPECIFIC ANTIBODIES AND USES THEREOF
#187BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#188COMBINATION THERAPY WITH TARGETED 4-1BB (CD137) AGONISTS
#189Universal reporter cell assay for specificity test of novel antigen binding moieties
#190Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#191Humanized antibodies against CEACAM1
#192ANTIGEN BINDING MOLECULES COMPRISING A TRIMERIC TNF FAMILY LIGAND
#193Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimer
#194Antibody-drug conjugates and uses thereof
#195Bispecific antibody formulation
#196TUMOR-TARGETED SUPERAGONISTIC CD28 ANTIGEN BINDING MOLECULES
#197Polynucleotides encoding humanized antibodies against CEACAM1
#198Tumor-targeted agonistic CD28 antigen binding molecules
#199COMBINATION IL-2 IMMUNOCONJUGATE THERAPY
#200INTERLEUKIN-2 IMMUNOCONJUGATE, A CD40 AGONIST, AND OPTIONALLY A PD-1 AXIS BINDING ANTAGONIST FOR USE IN METHODS OF TREATING CANCER
#201Anti-human CEACAM5 antibody Fab fragment
#202Bispecific antibodies against CEACAM5 and CD47
#203Anti-CEACAM5 antibodies and uses thereof
#204ANTIGEN BINDING RECEPTOR FORMATS
#205Antigen binding receptors specific for mutated Fc domains
#206Antibody-drug conjugates and uses thereof
#207Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis
#208Multimodal cancer therapy comprising chimeric viral/nonviral nanoparticles and anticancer agents
#209Single chain binding molecules comprising N-terminal ABP
#210BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF
#211MULTI-SITE SPECIFIC INTEGRATION CELLS FOR DIFFICULT TO EXPRESS PROTEINS
#212Antigen-binding molecules comprising a tumor necrosis factor (TNF) family ligand trimer
#213Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
#214Modulation of immunity and CEACAM1 activity
#215Anti-5T4 antibody-drug conjugate and use thereof
#216COMBINATION THERAPY OF TUMOR-TARGETED IL-2 VARIANT IMMUNOCYTOKINES AND ANTIBODIES AGAINST HUMAN PD-L1
#217METHODS FOR CREATING SYNTHETIC CHROMOSOMES HAVING GENE REGULATORY SYSTEMS AND USES THEREOF
#218CONDITIONAL AGONISTS OF IMMUNE RESPONSES
#219TUMOR TARGETING CONJUGATES AND METHODS OF USE THEREOF
#220NOVEL IMMUNOCONJUGATES
#221Immunoconjugates
#222RNA VIRUSES EXPRESSING IL-12 FOR IMMUNOVIROTHERAPY
#223Segregation Modulation for Immunotherapy
#224Re-directed immunotherapy
#225Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers
#226Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
#227C-TERMINALLY FUSED TNF FAMILY LIGAND TRIMER-CONTAINING ANTIGEN BINDING MOLECULES
#228ANTI-CEA ANTIBODIES
#229BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#230COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE
#231T cell recruiting polypeptides based on TCR alpha/beta reactivity
#232Nanobody dimers linked via C-terminally engineered cysteins
#233RNA VIRUSES FOR IMMUNOVIROTHERAPY
#234Efficacy of anti-HLA-DR antibody drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
#235Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
#236Antibody-drug conjugates and uses thereof
#237METHODS AND COMPOSITIONS FOR T-CELL IMMUNOTHERAPY
#238Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#239Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#240Bispecific T cell activating antigen binding molecules
#241Bispecific T cell activating antigen binding molecules
#242Single chain fusionconstructs comprising multimeric antibody fragments fused to collagen trimerization domains
#243Methods and compositions for combination immunotherapy
#244Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
#245Bispecific antibodies specifically binding to PD1 and LAG3
#246BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#247Subcutaneous administration of antibody-drug conjugates for cancer therapy
#248BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#249CELL-TARGETING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES
#250ANTIBODIES RECOGNIZING A CARBOHYDRATE CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS AND METHODS USING SAME
#251NIR-conjugated tumor-specific antibodies and uses thereof
#252COMBINATION THERAPY OF TUMOR-TARGETED IL-2 VARIANT IMMUNOCYTOKINES AND ANTIBODIES AGAINST HUMAN PD-L1
#253CEACAM1 BASED CANCER THERAPY AND DIAGNOSIS
#254Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
#255CEACAM1 MEDIATED PROTECTIVE IMMUNITY
#256COVALENT DISULFIDE-LINKED DIABODIES AND USES THEREOF
#257Fluorescent conjugates
#258Disease therapy by inducing immune response to Trop-2 expressing cells
#259Car t-cell therapy directed to LHR for the treatment of solid tumors
#260Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
#261Bispecific T cell activating antigen binding molecules
#262CAR-T LYMPHOCYTES ENGINEERED TO HOME TO LYMPH NODE B CELL ZONE, SKIN, OR GASTROINTESTINAL TRACT
#263ANTI-CEA ANTIBODIES
#264Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
#265Anti-CEACAM5 antibodies and uses thereof
#266Antibody-urease conjugates for therapeutic purposes
#267Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
#268Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
#269ANTIBODIES TO CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE (CEACAM)
#270ANTI-CEACAM1 RECOMBINANT ANTIBODIES FOR CANCER THERAPY
#271CROSSLINKING OF CD22 BY EPRATUZUMAB TRIGGERS BCR SIGNALING AND CASPASE-DEPENDENT APOPTOSIS IN HEMATOPOIETIC CANCER CELLS
#272CHIMERIC ACTIVATORS: QUANTITATIVELY DESIGNED PROTEIN THERAPEUTICS AND USES THEREOF
#273Combination therapy for inducing immune response to disease
#274Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
#275COMBINING ANTI-HLA-DR OR ANTI-TROP-2 ANTIBODIES WITH MICROTUBULE INHIBITORS, PARP INHIBITORS, BRUTON KINASE INHIBITORS OR PHOSPHOINOSITIDE 3-KINASE INHIBITORS SIGNIFICANTLY IMPROVES THERAPEUTIC OUTCOME IN CANCER
#276PRO-DRUG FORM (P2PDOX) OF THE HIGHLY POTENT 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED THERAPY OF CANCER
#277Stable compositions of high-concentration allotype-selected antibodies for small-volume administration
#278RNA viruses expressing IL-12 for immunovirotherapy
#279T-cell redirecting bispecific antibodies for treatment of disease
#280Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
#281Treatment method
#282Bispecific T cell activating antigen binding molecules
#283BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#284Antigen binding formats for use in therapeutic treatments or diagnostic assays
#285Chimeric antigen receptor and its use
#286Serum half-life extension using IgBD
#287Pharmaceutical compositions with resistance to soluble CEA
#288RNA viruses for immunovirotherapy
#289Dock-and-Lock (DNL) Complexes for Therapeutic and Diagnostic Use
#290Immunoconjugates
#291Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells
#292Combination IL-2 immunoconjugate therapy
#293Humanized antibodies against CEACAM1
#294ADENOVIRAL TARGETING, COMPOSITIONS AND METHODS THEREFOR
#295Immunotherapy with Binding Agents
#296Fluorescent conjugates
#297T-cell redirecting bispecific antibodies for treatment of disease
#298Combination therapy for inducing immune response to disease
#299Compositions And Methods For Modulating And Redirecting Immune Responses
#300Antibody-drug conjugates and uses thereof